EDNRA and chronic kidney disease: While several safety concerns did put a temporary halt on the widespread use of some earlier endothelin receptor antagonists, ZENITH-CKD proved that a highly selective ETA antagonist combined with an SGLT2i is a safe and efficacious therapy for slowing down eGFR decline and reducing albuminuria in both diabetic and non-diabetic CKD.